Please assess the completion status of the following clinical trial:

Trial Title: Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Age: 18 months up to 60 months (5th birthday);~* Onset of clinical manifestations related to mucopolysaccharidosis type IIIB (MPSIIIB);~* NAGLU activity in peripheral blood cell and/or cultured fibroblast extracts of less than 10% of controls;~* Patient affiliated to, or covered by a French social security regimen, or European patients with European Health Insurance Card;~* Family understanding the procedure and the informed consent;~* Signed informed consent by both parents or legal representative;~* Vital laboratory parameters within normal range.~Exclusion Criteria:~* Presence of brain atrophy on baseline MRI judged on a cortico-dural distance of more than 0.6 cm;~* Any condition that would contraindicate general anesthesia;~* Any other permanent medical condition not related to MPSIIIB that could contraindicate the study participation;~* No independent walking (ability to walk without help);~* Any medication aiming at modifying the natural course of MPSIIIB given during the 6 months before vector injection (sleep and mood regulators are accepted);~* Any condition that would contraindicate treatment with Modigraf®, Cellcept® and prednisolone (Solupred® and Solumedrol®).

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 60 Months
- Healthy Volunteers: f

Study Arms:
- rAAV2/5-hNAGLU (Type: EXPERIMENTAL): Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).

Based on this trial design, predict the completion outcome and termination type (if applicable).